The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study
Open accessAbstract
Purpose: To analyze the prognostic significance of NPM1 mutations, and the associated gene- and microRNA-expression signatures in older patients with de novo, cytogenetically normal acute myeloid leukemia (CN-AML) treated with intensive chemotherapy. Patients and Methods: One hundred forty-eight adults age ≥ 60 years with de novo CN-AML, enrolled onto Cancer and Leukemia Group B protocols 9720 and 10201, were studied at diagnosis for NPM1, FLT3, CEBPA, and WT1 mutations, and gene- and microRNA-expression profiles. Results: Patients with NPM1 mutations (56%) had higher complete remission (CR) rates (84% v 48%; P < .001) and longer disease-free survival (DFS; P = .047; 3-year rates, 23% v 10%) and overall survival (OS; P < .001; 3-year rates, 35% v 8%) than NPM1 wild-type patients. In multivariable analyses, NPM1 mutations remained independent predictors for higher CR rates (P < .001) and longer DFS (P = .004) and OS (P < .001), after adjustment for other prognostic clinical and molecular variables. Unexpectedly, the prognostic impact of NPM1 mutations was mainly observed in patients ≥ 70 years. Gene- and microRNA-expression profiles associated with NPM1 mutations were similar across older patient age groups and similar to those in younger (< 60 years) patients with CN-AML. These profiles were characterized by upregulation of HOX genes and their embedded microRNAs and downregulation of the prognostically adverse MN1, BAALC, and ERG genes. Conclusion: NPM1 mutations have favorable prognostic impact in older patients with CN-AML, especially those age ≥ 70 years. The gene- and microRNA-expression profiles suggest that NPM1 mutations constitute a marker defining a biologically homogeneous entity in CN-AML that might be treated with specific and/or targeted therapies across age groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO classification of haematolymphoid tumours
Gaillard, F., Weerakkody, Y., & Sharma, R. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,776
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
Howlader, N. (2011) · Medical Entomology and Zoology · Cited by 2,612
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628 · cited 4×
“the NPM1 gene being the most frequent genetic alterations.(13-20) Indeed, AML with NPM1 mutations has been added as a provisional entity in the 2008 World Health Organization classification of AML.”
BackgroundResultInfluentialByrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
Age and acute myeloid leukemia
Appelbaum, F. R., Gundacker, H., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,350
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias
Calin, G. A., Liu, C.-G., Sevignani, C., Ferracin, M., Felli, N., Dumitru, C. D., Shimizu, M., Cimmino, A., Zupo, S., Dono, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404432101 · Cited by 1,285
A microRNA DNA methylation signature for human cancer metastasis
Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., Montuenga, L. M., Rossi, S., Nicoloso, M. S., Faller, W. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803055105 · Cited by 1,078
Juliusson, G., Antunovic, P., Derolf, Å., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wahlin, A., & Höglund, M. (2009) · Blood · doi:10.1182/blood-2008-07-172007 · Cited by 987
Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I.-M., Head, D. R., Appelbaum, F. R., & Willman, C. L. (1997) · Blood · doi:10.1182/blood.v89.9.3323 · Cited by 859
Döhner, K., Schlenk, R. F., Habdank, M., Scholl, C., Rücker, F. G., Corbacioglu, A., Bullinger, L., Fröhling, S., Döhner, H., & for the AML Study Group (AMLSG) (2005) · Blood · doi:10.1182/blood-2005-05-2164 · Cited by 849
A Southwest Oncology Group study
Jenkins, T. R., Tangen, C. M., Macdonald, J. S., Weiss, G. R., Chapman, R. M., & Hantel, A. (1993) · Cited by 773
Metabolism and regulation of canonical histone mRNAs: life without a poly(A) tail
Marzluff, W. F., Wagner, E. J., & Duronio, R. J. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2438 · Cited by 764
Gale, R. E., Green, C., Allen, C., Mead, A. J., Burnett, A. K., Hills, R. K., & Linch, D. C. (2008) · Blood · doi:10.1182/blood-2007-08-109090 · Cited by 745
Thiede, C., Koch, S., Creutzig, E., Steudel, C., Illmer, T., Schaich, M., Ehninger, G., & (DSIL), F. T. D. S. L. (2006) · Blood · doi:10.1182/blood-2005-08-3167 · Cited by 736
Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M. F., Haferlach, T., Hiddemann, W., & Falini, B. (2005) · Blood · doi:10.1182/blood-2005-06-2248 · Cited by 713
Verhaak, R. G. W., Goudswaard, C. S., van Putten, W., Bijl, M. A., Sanders, M. A., Hugens, W., Uitterlinden, A. G., Erpelinck, C. A. J., Delwel, R., Löwenberg, B., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2168 · Cited by 618
Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia‐Manero, G., Wierda, W., Pierce, S., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 610
let-7 microRNAs in development, stem cells and cancer
Büssing, I., Slack, F. J., & Großhans, H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.07.001 · Cited by 607
Mrózek, K., Marcucci, G., Paschka, P., Whitman, S. P., & Bloomfield, C. D. (2007) · Blood · doi:10.1182/blood-2006-06-001149 · Cited by 552
Self-citationBazzoni, F., Rossato, M., Fabbri, M., Gaudiosi, D., Mirolo, M., Mori, L., Tamassia, N., Mantovani, A., Cassatella, M. A., & Locati, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810909106 · Cited by 548 · cited 1×
“Also overexpressed were members of the let-7 family, which target oncogenes RAS and MYC(63); miR-100, upregulated in t(15;17)-positive AML(64,65); and miR-9, which targets NF B and can be hypermethylated in cancer.(66,67) Downregulated were miR-126, the expression of which we recently positively correlated with MN1 ex…”
BackgroundHox cofactors in vertebrate development
Moens, C. B., & Selleri, L. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2005.10.032 · Cited by 510
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
Garzon, R., Garofalo, M., Martelli, M. P., Briesewitz, R., Wang, L., Fernandez-Cymering, C., Volinia, S., Liu, C.-G., Schnittger, S., Haferlach, T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800135105 · Cited by 500
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations
Li, Z., Lu, J., Sun, M., Mi, S., Zhang, H., Luo, R. T., Chen, P., Wang, Y., Yan, M., Qian, Z., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808266105 · Cited by 457
Self-citationGoldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., & Clark, R. E. (2001) · Blood · doi:10.1182/blood.v98.5.1302 · Cited by 438
MicroRNA fingerprints during human megakaryocytopoiesis
Garzon, R., Pichiorri, F., Palumbo, T., Iuliano, R., Cimmino, A., Aqeilan, R., Volinia, S., Bhatt, D., Alder, H., Marcucci, G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600587103 · Cited by 414
Self-citationMicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
Jongen-Lavrencic, M., Sun, S. M., Dijkstra, M. K., Valk, P. J. M., & Löwenberg, B. (2008) · Blood · doi:10.1182/blood-2008-01-133355 · Cited by 403
Baer, M. R., George, S. L., Dodge, R. K., O'Loughlin, K. L., Minderman, H., Caligiuri, M. A., Anastasi, J., Powell, B. L., Kolitz, J. E., Schiffer, C. A., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1224.h81602001224_1224_1232 · Cited by 366
Self-citationAlcalay, M., Tiacci, E., Bergomas, R., Bigerna, B., Venturini, E., Minardi, S. P., Meani, N., Diverio, D., Bernard, L., Tizzoni, L., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0560 · Cited by 357
Fox's in development and disease
Lehmann, O. J., Sowden, J. C., Carlsson, P., Jordan, T., & Bhattacharya, S. S. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00111-2 · Cited by 350
Büchner, T., Berdel, W. E., Haferlach, C., Haferlach, T., Schnittger, S., Müller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4245 · Cited by 338
Farag, S. S., Archer, K. J., Mrózek, K., Ruppert, A. S., Carroll, A. J., Vardiman, J. W., Pettenati, M. J., Baer, M. R., Qumsiyeh, M. B., Koduru, P. R., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4354 · Cited by 334
Self-citationKook, H., Lepore, J. J., Gitler, A. D., Lu, M. M., Wing-Man Yung, W., Mackay, J., Zhou, R., Ferrari, V., Gruber, P., & Epstein, J. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19137 · Cited by 332
Marcucci, G., Maharry, K., Radmacher, M. D., Mrózek, K., Vukosavljevic, T., Paschka, P., Whitman, S. P., Langer, C., Baldus, C. D., Liu, C.-G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5554 · Cited by 302
Self-citationFröhling, S., Schlenk, R. F., Kayser, S., Morhardt, M., Benner, A., Döhner, K., Döhner, H., & for the German-Austrian AML Study Group (2006) · Blood · doi:10.1182/blood-2006-04-014324 · Cited by 300
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia
Suzuki, T. (2005) · Blood · doi:10.1182/blood-2005-04-1733 · Cited by 277
Whitman, S. P., Ruppert, A. S., Radmacher, M. D., Mrózek, K., Paschka, P., Langer, C., Baldus, C. D., Wen, J., Racke, F., Powell, B. L., et al. (2008) · Blood · doi:10.1182/blood-2007-08-107946 · Cited by 266
Self-citationPaschka, P., Marcucci, G., Ruppert, A. S., Whitman, S. P., Mrózek, K., Maharry, K., Langer, C., Baldus, C. D., Zhao, W., Powell, B. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2058 · Cited by 258
Self-citationBaldus, C. D., Tanner, S. M., Ruppert, A. S., Whitman, S. P., Archer, K. J., Marcucci, G., Caligiuri, M. A., Carroll, A. J., Vardiman, J. W., Powell, B. L., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0359 · Cited by 241
Self-citationPatel, V. P., Kreider, B. L., Li, Y., Li, H., Leung, K., Salcedo, T., Nardelli, B., Pippalla, V., Gentz, S., Thotakura, R., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.7.1163 · Cited by 240
Falini, B., Bolli, N., Liso, A., Martelli, M. P., Mannucci, R., Pileri, S., & Nicoletti, I. (2009) · Leukemia · doi:10.1038/leu.2009.124 · Cited by 239
Marcucci, G., Baldus, C. D., Ruppert, A. S., Radmacher, M. D., Mrózek, K., Whitman, S. P., Kolitz, J. E., Edwards, C. G., Vardiman, J. W., Powell, B. L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6137 · Cited by 236
Self-citationAcute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
Estey, E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2731 · Cited by 235
Pellagatti, A., Jädersten, M., Forsblom, A.-M., Cattan, H., Christensson, B., Emanuelsson, E. K., Merup, M., Nilsson, L., Samuelsson, J., Sander, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610477104 · Cited by 233
Heuser, M., Beutel, G., Krauter, J., Döhner, K., von Neuhoff, N., Schlegelberger, B., & Ganser, A. (2006) · Blood · doi:10.1182/blood-2006-04-014845 · Cited by 232
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype
Boissel, N. (2005) · Blood · doi:10.1182/blood-2005-05-2174 · Cited by 224
Schlenk, R. F., Dohner, K., Kneba, M., Gotze, K., Hartmann, F., del Valle, F., Kirchen, H., Koller, E., Fischer, J. T., Bullinger, L., et al. (2009) · Haematologica · doi:10.3324/haematol.13378 · Cited by 210 · cited 2×
“To our knowledge, no study has analyzed the predictive significance of NPM1 mutations as a single marker in the context of other prognostic factors in older patients with CN-AML.(6,23-25) Therefore, we evaluated NPM1 mutations in a relatively large set of adults 60 years with CN-AML treated with intensive chemotherapy…”
BackgroundResultMicroRNAs in the Hox network: an apparent link to posterior prevalence
Yekta, S., Tabin, C. J., & Bartel, D. P. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2400 · Cited by 197
CD200 as a prognostic factor in acute myeloid leukaemia
Tonks, A., Hills, R., White, P., Rosie, B., Mills, K. I., Burnett, A. K., & Darley, R. L. (2007) · Leukemia · doi:10.1038/sj.leu.2404559 · Cited by 196
Langer, C., Radmacher, M. D., Ruppert, A. S., Whitman, S. P., Paschka, P., Mrózek, K., Baldus, C. D., Vukosavljevic, T., Liu, C.-G., Ross, M. E., et al. (2008) · Blood · doi:10.1182/blood-2007-11-124958 · Cited by 192
Self-citationMarcucci, G., Maharry, K., Whitman, S. P., Vukosavljevic, T., Paschka, P., Langer, C., Mrózek, K., Baldus, C. D., Carroll, A. J., Powell, B. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8720 · Cited by 192
Self-citationExpression patterns of microRNAs 155 and 451 during normal human erythropoiesis.
Masaki, S., Ohtsuka, R., Abe, Y., Muta, K., & Umemura, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.077 · Cited by 178
Langer, C., Marcucci, G., Holland, K. B., Radmacher, M. D., Maharry, K. S., Paschka, P., Whitman, S. P., Mrózek, K., Baldus, C. D., Vij, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6110 · Cited by 178
Self-citationBaldus, C. D., Liyanarachchi, S., Mrózek, K., Auer, H., Tanner, S. M., Guimond, M., Ruppert, A. S., Mohamed, N., Davuluri, R. V., Caligiuri, M. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400272101 · Cited by 173
Self-citationIroquois genes: genomic organization and function in vertebrate neural development
Gómez-Skarmeta, J. L., & Modolell, J. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00317-9 · Cited by 172
Pabst, O., Zweigerdt, R., & Arnold, H.-H. (1999) · Development · doi:10.1242/dev.126.10.2215 · Cited by 171
MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia
Benderra, Z., Faussat, A. M., Sayada, L., Perrot, J., Tang, R., Chaoui, D., Morjani, H., Marzac, C., Marie, J., & Legrand, O. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1895 · Cited by 154
Dynamic assembly of silent chromatin during thymocyte maturation
Su, R., Brown, K. E., Saaber, S., Fisher, A. G., Merkenschlager, M., & Smale, S. T. (2004) · Nature Genetics · doi:10.1038/ng1351 · Cited by 133
Baer, M. R., George, S. L., Caligiuri, M. A., Sanford, B. L., Bothun, S. M., Mrózek, K., Kolitz, J. E., Powell, B. L., Moore, J. O., Stone, R. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.0472 · Cited by 131
Self-citationRadmacher, M. D. (2006) · Blood · doi:10.1182/blood-2006-02-005538 · Cited by 122
Self-citationIdentification of cancer/testis-antigen genes by massively parallel signature sequencing
Chen, Y., Scanlan, M. J., Venditti, C. A., Chua, R. A., Theiler, G., Stevenson, B. J., Iseli, C., Gure, A. O., Vasicek, T., Strausberg, R. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502583102 · Cited by 112
Liao, C., Wang, X. Y., Wei, H. Q., Li, S. Q., Merghoub, T., Pandolfi, P. P., & Wolgemuth, D. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121540098 · Cited by 88
DiMartino, J. F., Lacayo, N. J., Varadi, M., Li, L., Saraiya, C., Ravindranath, Y., Yu, R., Sikic, B. I., Raimondi, S. C., & Dahl, G. V. H. (2006) · Leukemia · doi:10.1038/sj.leu.2404102 · Cited by 85
Mrózek, K. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000002 · Cited by 70
Self-citationScholl, S., Theuer, C. M., Scheble, V. J., Kunert, C., Heller, A., Mügge, L., Fricke, H., Höffken, K., & Wedding, U. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.01019.x · Cited by 69
Schneider, F., Hoster, E., Unterhalt, M., Schneider, S., Dufour, A. M., Benthaus, T., Mellert, G., Zellmeier, E., Bohlander, S. K., Feuring‐Buske, M., et al. (2009) · Blood · doi:10.1182/blood-2008-09-172668 · Cited by 58
Verstovšek, S., Kantarjian, H. M., Estey, E. H., Aguayo, A., Giles, F. J., Manshouri, T., Koller, C. A., Estrov, Z. E., Freireich, E. J., Keating, M. J., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402182 · Cited by 47
ETV6 and PDGFRB: a license to fuse
Lierman, E., & Cools, J. (2007) · Haematologica · doi:10.3324/haematol.11187 · Cited by 22
Expression of the NET family member Zfp503 is regulated by hedgehog and BMP signaling in the limb
McGlinn, E., Richman, J. M., Metzis, V., Town, L., Butterfield, N. C., Wainwright, B. J., & Wicking, C. (2008) · Developmental Dynamics · doi:10.1002/dvdy.21508 · Cited by 22
Cited by
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationMarcucci, G., Maharry, K., Wu, Y.-Z., Radmacher, M. D., Mrózek, K., Margeson, D., Holland, K. B., Whitman, S. P., Becker, H., Schwind, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3730 · Cited by 763
Self-citationMolecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Marcucci, G., Haferlach, T., & Döhner, H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2554 · Cited by 570
Self-citationAcute myeloid leukaemia in adults
Ferrara, F., & Schiffer, C. A. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61727-9 · Cited by 563
An update of current treatments for adult acute myeloid leukemia
Dombret, H., & Gardin, C. (2016) · Blood · doi:10.1182/blood-2015-08-604520 · Cited by 550
Metadata
- Authors
- Becker, H., Marcucci, G., Maharry, K., Radmacher, M. D., Mrózek, K., Margeson, D., Whitman, S. P., Wu, Y.-Z., Schwind, S., Paschka, P., Powell, B. L., Carter, T. H., Kolitz, J. E., Wetzler, M., Carroll, A. J., Baer, M. R., Caligiuri, M. A., Larson, R. A., & Bloomfield, C. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-02-01
- Volume
- 28
- Issue
- 4
- Pages
- 596-604
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2147010550
- Cited by
- 338
- References
- 70
- FWCI
- 18.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.